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serve as a demonstration that cord blood cells can differentiate into
non-hematopoietic tissues.
All children were prepared for transplant with myeloablative
chemotherapy consisting of busulfan, cyclophosphamide and anti-
thymocyte globulin. Prophylaxis against GvHD was administered
with cyclosporine and methylprednisolone. Supportive care was
provided with IVIG, G-CSF, low dose heparin for VOD prophy-
laxis, leukocyte depleted and irradiated PRBC and platelet trans-
fusions, total parenteral nutrition, prophylactic antiviral and anti-
fungal antibiotics and empiric antibiotic therapy for fever. Thirty
ﬁve young children with Hurler syndrome (MPS I) were trans-
planted with partially HLA mismatched unrelated donor umbilical
cord blood over the past 8 years. All had the severe phenotype.
Neutrophil (ANC 500/	L) and platelet (50k/	L) engraftment
occurred in a median of 20 and 63 days respectively. Moderate to
severe acute GvHD occurred in 28 % of patients. Extensive
chronic GvHD was not seen. Twelve percent of patients had
serious events, graft rejection (n  1), infectious deaths (n  3),
toxic death (n 1, hyperammonemia). All other patients (87%) are
surviving event-free for a median greater than 3 years. All surviving
children remain full donor chimeras and have shown increasing
velocities of gains of neurocognitive functions. Skeletal growth
improved with only 4/11 children with severe kyphosis requiring
orthopedic surgery post transplantation therapy. No child devel-
oped clinical cardiac disease and corneal clouding improved in all.
Additional children (60) with lysosomal storage diseases includ-
ing metachromatic leukodystrophy, adrenoleukodystrophy and
globoid leukodystrophy (Krabbe disease) have been transplanted
with unrelated donor umbilical cord blood over the past 9 years. In
asymptomatic children, disease was arrested before the onset of
neurologic dysfunction. In symptomatic children disease progres-
sion was arrested within 6-9 months of the transplant procedure. In
a child with advanced Krabbe disease who died 1 year post trans-
plant, engraftment of donor cells was noted in the brain. Differ-
entiation to oligodendrocytes was demonstrated in vitro and sub-
sequently, in vivo. In a child with MPS III (Sanﬁlippo syndrome),
donor cells differentiated into cardiac myocytes in the heart 6
months post transplant.
These studies suggest that cord blood is capable of transdiffer-
entiation into non-hematopoietic lineages. Further studies are
needed to fully deﬁne the potential of these cells for cellular
therapies and tissue repair.
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UNRELATED DONOR CORD BLOOD TRANSPLANTATION FOR CHILDREN
WITH HEMATOLOGICAL MALIGNANCIES
Zecca, M., Locatelli, F. Pediatric Hematology, IRCCS Policlinico San
Matteo, Pavia, Italy.
Cord blood (CB) contains a large amount of hematopoietic
progenitors and over the last decade has been largely employed to
transplant children with either malignant or non-malignant disor-
ders. Advantages related to the use of CB cells are represented by
the low risk of acute and chronic graft-versus-host disease
(GVHD), prompt availability of this source of hematopoietic pro-
genitors, which shortens the time needed to locate a suitable
donor, and by the possibility of performing transplants in the
presence of 1 or 2 HLA disparities in the donor/recipient pairs.
Both these latter two factors can be relevant for treating children
with malignancies, whose disease, often running an aggressive
clinical course, might not allow an extended period of time for
ﬁnding a suitable unrelated bone marrow donor. Hundreds of
children with acute lymphoblastic or myeloid leukemia have re-
ceived an allograft of unrelated CB cells. The experience derived
from these patients has demonstrated that results achieved with
this type of transplant are substantially comparable to those ob-
tained in children given bone marrow transplantation. In particu-
lar, the risk of leukemia recurrence is not increased after CB
transplantation. Disease status at time of transplantation is the
main factor inﬂuencing patient’s outcome, patients transplanted in
1st-2nd remission being those with the best results. Both a higher
transplant-related mortality and an increased risk of leukemia re-
currence contribute to the worse outcome of patients given the
allograft in more advanced disease. As most deaths occurring in
children given CB transplantation are due to infectious complica-
tions (related to both delayed hematopoietic recovery and lack of
adoptive transfer of memory T-cells) strategies able to accelerate
both hematopoietic and immune reconstitution could widen the
use of CB cells for transplantation.
13
THE ROLE OF CORD BLOOD TRANSPLANTATION IN THALASSEMIA
Walters, M. Oakland Children’s Hospital, Oakland, CA.
More than 20 years ago, the ﬁrst successful cure of 
-thalassemia
major by bone marrow transplantation was reported. Since then,
more than 1500 patients have been treated in this manner. In
Pesaro Italy where more than 1000 patients have received marrow
transplantation, the 20-year probability of thalassemia-free survival
is approximately 70%. Updated results strongly suggest that im-
proved outcomes across risk categories have occurred as effective
supportive care and conditioning regimen modiﬁcations have been
applied to this setting. As with other non-malignant conditions, the
alternative of increasingly effective supportive care also impacts
upon the decision to pursue transplantation, even when transplant
outcomes are very good. Umbilical cord blood (UCB) transplan-
tation, thus, must compare favorably to proven therapeutic alter-
natives before its use can be expanded. UCB is an attractive alter-
native to other stem cell sources due to its decreased incidence of
graft-versus-host disease (GVHD) and rapid tempo of immuno-
logical reconstitution after transplantation. Initial results of UCB
transplantation for thalassemia suggest that acceptable out-
comes are possible if measures are taken to mitigate the risk of
graft rejection. Among 44 patients with sickle cell disease or
thalassemia who received augmented conditioning therapy, the
event-free survival was 94% compared to 62% among those who
received a standard combination of busulfan and cyclophosph-
amide, with or without horse anti-thymocyte globulin. These
early results also support the importance of banking efforts to
expand the collection of related and unrelated UCB units. The
clinical experience of unrelated UCB transplantation for thalas-
semia remains very limited. New techniques to prevent GVHD
and promote engraftment, coupled with reﬁned donor selection
criteria should expand the availability of transplantation for
thalassemia major.
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RESULTS OF UNRELATED CORD BLOOD TRANSPLANT IN PATIENTS
WITH BONE MARROW FAILURE SYNDROMES
Gluckman, E. Eurocord, Hospital Saint Louis, Paris, France.
In Fanconi anemia (FA) patients without an HLA identical bone
marrow donor, search for an unrelated cord blood donor is an
option, however few results have been reported so far. In the
Eurocord registry, we have analyzed 44 patients with FA receiving
an unrelated cord blood transplant (UCBT). The median age was
7.7 years and median follow-up 20 months (8-83). At UCBT, the
median number of neutrophils was 620/mm3 and 13 patients had
received more than 20 red blood cell transfusions. The cord blood
was HLA mismatched in 37 patients (HLA-A and B by serology
and DRB1 high resolution typing, 5/6  21, 4/6  12 and 3/6 
3). The median number of nucleated cells (NC) at freezing was 5.5
 107/kg and at infusion 4.7  107/kg. Eighteen patients received
CY and irradiation based preparative regimens, 12 patients ﬂudara-
bine (FLU) containing regimen, 6 CY alone and 8 other regimens.
GVHD prophylaxis consisted of CSA and MTX (43%) or CsA
alone (23%). Results: Neutrophil recovery at day 60 was 56% 
8%. Two factors were associated with higher probability of neu-
trophil recovery (cell dose and number of HLA disparities). Acute
GVHD (II-IV) was 23%  6% (grade II  7%, III  7%, IV 
11%) and chronic GVHD occurred in 4/21 patients at risk (19%).
Two year survival was 36%  7%. In univariate analysis factors
associated with better survival were negative CMV serology,
NC at freezing or infused, higher neutrophil count at UCBT
and FLU containing regimen. In multivariate analysis only two
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